Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates news across four distinct healthcare sectors: medical devices, diagnostics, nutrition, and pharmaceuticals. This diversification produces a steady flow of announcements spanning FDA approvals for cardiac devices and diabetes technology, clinical trial results, product launches, and quarterly earnings reports.
Abbott's medical devices business drives significant news volume through regulatory clearances for cardiovascular implants, continuous glucose monitoring innovations, and structural heart interventions. The FreeStyle Libre platform and cardiac rhythm management portfolio generate regular updates on expanded indications, international approvals, and clinical evidence supporting device efficacy.
Quarterly earnings releases reveal segment-by-segment performance across Abbott's four divisions, providing insight into medical device adoption rates, diagnostic testing volumes, nutrition product demand, and emerging market pharmaceutical sales. As a Dividend Aristocrat with more than five decades of consecutive dividend increases, Abbott's dividend announcements attract income-focused investor attention.
Product development news includes CE Mark approvals for European markets, FDA 510(k) clearances, breakthrough device designations, and clinical study enrollments. Abbott's global manufacturing footprint and commercial presence in over 160 countries means regulatory and market access news spans multiple geographic regions.
Bookmark this page to follow Abbott's medical device innovations, diagnostic technology advancements, nutrition product developments, and financial performance updates as they are announced.
Abbott has partnered with Epic to integrate data from its FreeStyle Libre continuous glucose monitoring (CGM) systems directly into Epic's electronic health record systems in the U.S. This first-of-its-kind integration allows data from users' LibreView accounts to automatically link to Epic's platform.
Through Epic's Aura software, over 575,000 U.S. healthcare providers serving 280 million patients will gain streamlined access to patients' glucose data within their existing workflows. The collaboration aims to enhance care efficiency by enabling providers to view glucose data before, during, and after patient consultations.
Key benefits include:
- Improved workflow efficiency for healthcare providers
- Seamless access to CGM data in patient charts
- Enhanced patient-provider collaboration
- More time for care management versus administrative tasks
Abbott plans to expand this model to other medical devices and connected care platforms in the future. Healthcare providers interested in updates can contact Abbott at Libre.Epic@abbott.com.
Abbott (NYSE: ABT) announced breakthrough results from its AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch area. The study demonstrated successful implantation of the AVEIR CSP leadless pacemaker technology.
Additionally, Abbott has initiated the ASCEND CSP pivotal clinical trial to evaluate their investigational CSP Implantable Cardioverter-Defibrillator lead, which will enroll up to 414 people across 70 global sites. The company received FDA Breakthrough Device Designations for both the AVEIR CSP leadless pacemaker system and the CSP ICD lead for left bundle branch area pacing (LBBAP).
Abbott's UltiPace™ Pacing Lead became the first FDA-approved stylet-driven lead indicated for left bundle branch area placement, marking significant progress in their cardiac rhythm management portfolio.
Abbott (NYSE: ABT) has revealed compelling 12-month data from its Volt CE Mark Study, demonstrating sustained benefits of the Volt™ PFA System for treating atrial fibrillation. The study, presented at the 2025 Heart Rhythm Society meeting, showed impressive results for both paroxysmal (PAF) and persistent AFib patients.
Key findings after 12 months include:
- 83.5% of PAF patients and 58.1% of PersAF patients remained arrhythmia-free
- Quality of life scores improved significantly from 64.1 to 88.1
- Only 2.7% of patients experienced primary safety endpoint events
- Zero patients suffered from common PFA therapy complications
- System achieved results with just 4.7 applications per vein on average
The Volt PFA System utilizes high-energy electrical pulses for targeted cardiac tissue treatment and can be administered under either light sedation or general anesthesia, offering procedural flexibility.
Abbott (NYSE: ABT) reported strong first-quarter 2025 results with reported sales growth of 4.0% and organic sales growth of 6.9%. First-quarter GAAP diluted EPS reached $0.76, while adjusted diluted EPS was $1.09, showing double-digit growth year-over-year.
Key financial metrics include a reported gross margin of 52.8% and adjusted gross margin of 57.1%, reflecting a 140 basis point increase. The company's operating margin stood at 16.3%, with adjusted operating margin at 21.0%, up 130 basis points.
Notable developments include: CE Mark approval for Volt™ PFA System, initiation of the TECTONIC trial for Coronary IVL System, and positive two-year data from TRILUMINATE™ trial for TriClip™ device. Abbott reaffirmed its full-year 2025 guidance, projecting organic sales growth of 7.5-8.5% and adjusted diluted EPS of $5.05-$5.25.
Abbott (NYSE: ABT) announced positive two-year data from its TRILUMINATE™ Pivotal trial for the TriClip™ transcatheter edge-to-edge repair (TEER) system, designed to treat tricuspid regurgitation (TR). The results, presented at ACC.25 and published in Circulation, demonstrate significant improvements over medical therapy.
Key findings after two years include:
- Significant reduction in heart failure hospitalizations (0.19 vs. 0.26 events/patient-year) in the treatment group
- 84% of TriClip patients achieved moderate or less TR grade versus 21% in control group
- Patients showed over 15-point improvement in quality of life scores (KCCQ)
- More than half of control group patients (142 of 241) crossed over to receive TriClip therapy, showing similar improvements
The data confirms TriClip as a safe and effective treatment option for TR patients who are not suitable for open-heart surgery, offering sustained benefits in reducing valve leakage and improving quality of life.
Abbott (NYSE: ABT) has received CE Mark approval in Europe for its Volt™ PFA System, designed to treat atrial fibrillation (AFib). The system has begun commercial cases in the EU following strong clinical trial results showing 99.1% success rate in pulmonary vein isolation.
The Volt PFA System offers a single-catheter approach for mapping, pacing, and ablating, integrating with Abbott's EnSite™ X EP system. Key features include simplified workflow, efficient energy delivery through a proprietary balloon-in-basket design, and procedural flexibility allowing for light sedation or general anesthesia.
The approval comes as approximately 8 million Europeans over 65 live with AFib, a number expected to double in 30 years. The system is currently under evaluation in the VOLT-AF IDE Study with nearly 400 patients enrolled, with 12-month follow-up expected later this year.
FAQ
What is the current stock price of Abbott Labs (ABT)?
What is the market cap of Abbott Labs (ABT)?
